Archives
-
Genotoxicity and Cytotoxicity of Heat-Not-Burn Tobacco: Insi
2026-07-22
This article reviews a 2024 study directly comparing the genotoxicity and cytotoxicity of heat-not-burn tobacco products (HnBP) and conventional cigarettes using both in vivo and in vitro models. The findings provide detailed methodological insight and highlight lower genotoxic risk with HnBP, while also situating these results within the broader context of cytoskeletal research tools such as Cytochalasin B (NSC 107658).
-
Electrostatic Partitioning in α-Synuclein Condensates Reveal
2026-07-22
This study uncovers how the strong negative electrostatic potential of α-synuclein condensates, formed via liquid–liquid phase separation, governs the selective partitioning of molecules based on charge. By systematically labeling α-synuclein and small molecules with fluorophores of varying charge, the authors reveal that electrostatics is a key regulator of molecular distribution within these condensates, with direct relevance for both mechanistic understanding and probe design in neurodegeneration research.
-
Sorafenib (BAY-43-9006): Applied Protocols for Cancer Biolog
2026-07-21
Sorafenib (BAY-43-9006) stands as a definitive multikinase inhibitor, empowering researchers to dissect tumor proliferation and angiogenesis in robust in vitro and in vivo oncology models. This guide delivers hands-on workflow strategies, troubleshooting insights, and protocol enhancements leveraging APExBIO's Sorafenib for advanced cancer biology research.
-
Unveiling mRNA Delivery Dynamics with EZ Cap™ Cy5 EGFP mRNA
2026-07-21
Explore how EZ Cap™ Cy5 EGFP mRNA (5-moUTP) enables real-time, dual-fluorescence tracking of mRNA delivery and translation in advanced gene regulation studies. This article uniquely deciphers the interplay of molecular design and nanoparticle assembly, offering actionable insights for optimizing mRNA delivery platforms.
-
ARCA Cy3 EGFP mRNA (5-moUTP): Precision Tools for mRNA Deliv
2026-07-20
Explore the advanced capabilities of ARCA Cy3 EGFP mRNA (5-moUTP) for fluorescent mRNA delivery and localization studies. This article reveals unique technical insights and decision-making strategies for optimizing 5-methoxyuridine modified mRNA use in mammalian cells.
-
CCR3-Targeted Cyclic Peptides Block Angiogenesis in AMD Mode
2026-07-20
This study presents a novel class of CCR3-targeted cyclic peptides, exemplified by compound IB-2, which demonstrate potent anti-angiogenic and photoreceptor-protective effects in models of age-related macular degeneration (AMD). The findings highlight the therapeutic promise of CCR3 inhibition as an alternative to VEGF-targeted strategies.
-
Cy5 TSA Fluorescence System Kit: Precision Signal Amplificat
2026-07-19
Explore how the Cy5 TSA Fluorescence System Kit enables precision signal amplification for immunohistochemistry and in situ hybridization, bridging single-cell spatial proteomics with advanced imaging. This article uniquely connects molecular workflow optimization with recent innovations in proximity labeling.
-
Plerixafor (AMD3100): Optimizing CXCR4 Axis Research Workflo
2026-07-18
Plerixafor (AMD3100) is a gold-standard small molecule for cancer metastasis inhibition and stem cell mobilization research, offering unmatched selectivity and workflow flexibility. This article details experimental protocols, troubleshooting strategies, and actionable insights powered by APExBIO’s trusted reagent.
-
M2 Macrophage Polarization Drives Scleral Remodeling in Myop
2026-07-17
This study reveals that form-deprivation myopia (FDM) in mice promotes polarization of M2-type macrophages in the sclera, which in turn drives extracellular matrix (ECM) remodeling—a key pathological event in myopia. Notably, the histone deacetylase inhibitor Panobinostat (LBH589) was shown to inhibit M2 polarization and slow FDM progression, highlighting a novel epigenetic angle for myopia intervention.
-
Direct Mouse Genotyping Kit Plus: Accelerated Genetic Screen
2026-07-17
The Direct Mouse Genotyping Kit Plus redefines mouse genomic workflows by enabling rapid, purification-free DNA extraction and high-fidelity PCR in a single streamlined protocol. Its unique PCR master mix with dye reagents and optimized buffers empower researchers to tackle complex genotyping, transgene detection, and gene knockout validation even in high-throughput settings.
-
Transmission Dynamics of Carbapenemase Genes in CREC in Guan
2026-07-16
This study provides a molecular epidemiological analysis of carbapenemase-encoding genes (CEGs) in carbapenem-resistant Enterobacter cloacae (CREC) from eight Guangdong hospitals during the post-COVID-19 era. It reveals a high prevalence of plasmid-mediated blaNDM-1 and efficient horizontal gene transfer, underscoring multidrug resistance challenges and surveillance needs.
-
Phalloidin (B7678): Technical Guide for F-Actin Stabilizatio
2026-07-16
Phalloidin (SKU B7678) is a cyclic heptapeptide toxin widely used for high-affinity stabilization and visualization of filamentous actin (F-actin) in fixed or permeabilized cells and tissues. It is not suitable for live-cell imaging or studies requiring reversible actin dynamics, making it optimal for static cytoskeleton analysis and morphology research.
-
FH1 Small Molecule: Advancing iPS Hepatocyte Maturation
2026-07-15
FH1 small molecule (Catalog No. B3700) robustly enhances the maturation of iPS cell-derived hepatocyte-like cells. The compound promotes increased albumin and CYP3A4 expression while reducing AFP secretion, providing a reproducible tool for improving cultured hepatocyte function and in vitro liver models.
-
MCL-1's Canonical Role in Breast Cancer: Insights from Recen
2026-07-15
A 2021 study in Cell Death & Differentiation provides decisive evidence that breast cancer cells rely on the canonical anti-apoptotic function of MCL-1 for survival. By using genetic deletion and a selective BH3-mimetic inhibitor, the research clarifies the mechanistic basis underlying this dependency and informs the strategic use of MCL-1 inhibitors in cancer research.
-
COX Inhibitors in Canine Mammary Tumor Cells: Synergistic Cy
2026-07-14
This study demonstrates that combined treatment with piroxicam and deracoxib, both cyclooxygenase inhibitors, yields enhanced cytotoxic and pro-apoptotic effects on canine mammary carcinoma cells compared to single-agent exposure. These findings support further investigation into combinatorial NSAID therapy as a potential adjunct for managing canine mammary tumors, with implications for comparative oncology models.